4.3.2019
EN
Official Journal of the European Union
C 82/24
Judgment of the General Court of 12 December 2018 — Biogaran v Commission
(Case T-677/14) (1)
((Competition - Agreements, decisions and concerted practices - Market for perindopril, a medicinal product intended for the treatment of cardiovascular diseases, in its originator and generic versions - Decision finding an infringement of Articles 101 TFEU and 102 TFEU - Agreements intended to delay, or even prevent, the market entry of generic versions of perindopril - Participation of a subsidiary in the infringement committed by its parent company - Imputation of the infringement - Joint and several liability - Ceiling of the fine))
(2019/C 82/26)
Language of the case: French
Parties
Applicant: Biogaran (Colombes, France) (represented by: T. Reymond, O. de Juvigny and J. Jourdan, lawyers)
Defendant: European Commission (represented initially by F. Castilla Contreras, T. Vecchi and B. Mongin, and subsequently by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents)
Re:
Application under Article 263 TFEU for annulment of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU [Case AT.39612 — Perindopril (Servier)] in so far as it concerns the applicant and, in the alternative, for reduction of the fine imposed on the applicant by that decision.
Operative part of the judgment
The Court:
1.
Dismisses the action;
2.
Orders Biogaran to pay the costs.
(1) OJ C 395, 10.11.2014.
Full & Egal Universal Law Academy